About 323,050 results

Racial disparities in endometrial cancer
Wesley Burkett, MD

Jun 23rd, 2022 - Endometrial cancer (EC) is the most common gynecologic malignancy and is the fourth most common cancer seen in U. S.

Pediatric HCC: Histologic subtypes demonstrate distinct clinical patterns

Jun 23rd, 2022 - Key clinical point: The pediatric hepatocellular carcinoma (HCC) subtypes fibrolamellar carcinoma (FLC) and conventional HCC (cHCC) can be considered nonequivalent entities because they show different anatomic patterns and outcomes together with their known molecular differences. Major finding: HCC subtypes were significantly different in presentation and behavior, with increased lymph node inv.

Unresectable HCC: Differential efficacy of atezolizumab plus bevacizumab according to hepatic function grade

Jun 23rd, 2022 - Key clinical point: Atezolizumab plus bevacizumab (Atez/Bev) shows potent therapeutic efficacy against unresectable hepatocellular carcinoma (uHCC) in patients with a good hepatic function, classified as Child-Pugh A (CP-A), but has decreased efficacy in those with CP-B. Major finding: Patients with CP-A vs.

Atezolizumab plus bevacizumab offers a better prognosis than lenvatinib in unresectable HCC

Jun 23rd, 2022 - Key clinical point: Therapy with atezolizumab plus bevacizumab (Atez/Bev) vs. lenvatinib in the first-line setting may confer a survival benefit in patients with unresectable hepatocellular carcinoma (uHCC).

HCC with Child-Pugh B cirrhosis: Nivolumab a promising first-line systemic treatment option

Jun 23rd, 2022 - Key clinical point: Nivolumab may serve as a first-line systemic treatment option in patients with hepatocellular carcinoma (HCC) and Child-Pugh B (CP-B) cirrhosis. Major finding: Patients receiving nivolumab vs.

NAFLD significantly increases the risk for HCC

Jun 23rd, 2022 - Key clinical point: Nonalcoholic fatty liver disease (NAFLD) is independently associated with an increased risk for hepatocellular carcinoma (HCC). Major finding: NAFLD significantly increased the risk for HCC (hazard ratio [HR] 1.

ER+/HER2− BC: Age and Ki-67 index predict nodal response to NAC

Jun 23rd, 2022 - Key clinical point: In estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) neoadjuvant chemotherapy (NAC) should be considered to enable axillary conservation in patients aged <50 years with Ki67 ≥20%. Major finding: Both Ki67 ≥20% (adjusted odds ratio [aOR] 2.

Similar prognosis in pregnant vs. nonpregnant BC patients receiving chemotherapy

Jun 23rd, 2022 - Key clinical point: Patients with breast cancer (BC) treated with standard chemotherapy during pregnancy show comparable prognosis to young nonpregnant patients with BC, supporting chemotherapy initiation in pregnant women with BC as indicated. Major finding: Median follow-up was 66.

Male infertility and breast cancer: Is there a link?

Jun 23rd, 2022 - Key clinical point: Male-origin infertility was associated with an increased risk for breast cancer (BC) in men. Major finding: Risk for BC was significantly higher in men diagnosed with infertility (odds ratio [OR] 2.

Artificial intelligence: The Netflix of cancer treatment
Lucas Franki, Richard Franki et. al.

Jun 23rd, 2022 - Chemotherapy, now streaming at just $15. 99 a month! It’s a lazy Sunday and you flip on Netflix, looking for something new to watch.

Breast cancer: Epigallocatechin-3-gallate prevents dermatitis in patients receiving radiotherapy

Jun 23rd, 2022 - Key clinical point: Patients who received adjuvant radiotherapy for breast cancer (BC) experienced a significant reduction in radiation-induced dermatitis (RID) incidence and severity after the prophylactic use of epigallocatechin-3-gallate (EGCG) solution. Major finding: Incidence rates of grade ≥2 RID (50.

Metastatic BC and brain metastases: Etirinotecan pegol fails to improve survival in phase 3

Jun 23rd, 2022 - Key clinical point: Etirinotecan pegol failed to prolong survival compared with chemotherapy in patients with metastatic breast cancer (BC) and stable pretreated brain metastases (BM). Major finding: The median overall survival (hazard ratio [HR] 0.

Adjuvant radiotherapy less toxic in prone vs. supine position in BC patients with heavy breasts

Jun 23rd, 2022 - Key clinical point: Adjuvant breast intensity-modulated radiotherapy (IMRT) in the prone vs. supine position was less toxic in women with large breast size and early-stage breast cancer (BC) who underwent breast-conserving surgery (BCS).

Elacestrant prolongs survival in previously treated ER+/HER2− advanced BC

Jun 23rd, 2022 - Key clinical point: Elacestrant significantly improved progression-free survival (PFS) compared with standard-of-care (SOC) endocrine monotherapy in previously treated patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (BC) with a manageable safety. Major finding: Elacestrant vs.

Metformin disappoints in high-risk operable breast cancer

Jun 23rd, 2022 - Key clinical point: In patients with high-risk operable breast cancer (BC) and without diabetes, adding metformin to standard BC treatment did not improve the invasive disease-free survival (iDFS) rate, regardless of estrogen receptor/progesterone receptor (ER/PgR) status. Major finding: The incidence rates of iDFS events were similar between the metformin and placebo groups in patients with ER.

Advanced TNBC: Camrelizumab + apatinib and eribulin shows promise in heavily pretreated patients

Jun 23rd, 2022 - Key clinical point: The combination of camrelizumab, apatinib, and eribulin demonstrated a favorable efficacy and a manageable safety profile in patients with heavily pretreated advanced triple negative breast cancer (TNBC). Major finding: The objective response rate (ORR), disease control rate, and median progression-free survival in the overall cohort were 37.

Primary BC: Weekly vs. every-3-week nab-paclitaxel improves pCR but with higher toxicity

Jun 23rd, 2022 - Key clinical point: Adding denosumab to anthracycline/taxane-based neoadjuvant chemotherapy (NACT) did not improve pathological complete response (pCR) rates, but a weekly vs. every-3-week nanoparticle albumin-bound ( nab)-paclitaxel regimen improved pCR rates in patients with early breast cancer (BC), although the toxicity was higher.

A Scrotal Rash Lasting Months in a Man With Genital Edema

Jun 23rd, 2022 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills using the following patient scenario and corresponding questions. If you have a case you would like to suggest for a future Case Challenge, please conta...

Aging HIV Patients Face Comorbidities and Hospitalizations

Jun 23rd, 2022 - Thanks to effective treatment, people with HIV are living longer. But as they age, they face higher rates of age-related comorbidities and hospitalizations, according to a recent study of hospitalized patients. Decisionmakers will need to allocate resources, train providers, and plan ways to manage chronic diseases, such as diabetes and cancer, among geriatric HIV inpatients, according to the a...

After Cancer, Text Messages Up Exercise and Reduce Late Effects

Jun 23rd, 2022 - Sending a text with a brief motivational intervention (MI) to parents of childhood cancer survivors substantially increased their child's physical activity level compared with control persons and also reduced treatment-related late effects. The findings come from a randomized trial of 161 children (median age, 12.4 years) who had recovered after leukemia, lymphoma, or brain tumors. "Physical ac...